These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19450075)

  • 1. Principal components analysis of drug expenditure and utilisation trends for major therapeutic classes in US Medicaid programmes.
    Guo JJ; Jing Y; Nguyen K; Fan H; Li X; Kelton CM
    J Med Econ; 2008; 11(4):671-94. PubMed ID: 19450075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
    Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
    Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in prescription drug expenditures by Medicaid enrollees.
    Banthin JS; Miller GE
    Med Care; 2006 May; 44(5 Suppl):I27-35. PubMed ID: 16625061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid expenditures and utilization in the Medicaid system.
    Brixner DI; Oderda GM; Roland CL; Rublee DA
    J Pain Palliat Care Pharmacother; 2006; 20(1):5-13. PubMed ID: 16687350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effect of newer medication adoption in an older Medicaid cohort.
    Shireman TI; Rigler SK; Jachna CM; Griebling TL; Eng ML
    J Am Geriatr Soc; 2005 Aug; 53(8):1366-73. PubMed ID: 16078963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991-2009.
    Gorevski E; Bian B; Kelton CM; Martin Boone JE; Guo JJ
    Ann Pharmacother; 2012 Apr; 46(4):503-12. PubMed ID: 22454448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of access restrictions on the vintage of drugs used by Medicaid enrollees.
    Lichtenberg FR
    Am J Manag Care; 2005 Jan; 11 Spec No():SP7-13. PubMed ID: 15700904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in health care expenditures, utilization, and health status among US adults with spine problems, 1997-2006.
    Martin BI; Turner JA; Mirza SK; Lee MJ; Comstock BA; Deyo RA
    Spine (Phila Pa 1976); 2009 Sep; 34(19):2077-84. PubMed ID: 19675510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991-2009.
    Desai VC; Cavanaugh TM; Kelton CM; Guo JJ; Heaton PC
    Clin Ther; 2012 Oct; 34(10):2118-2131.e1. PubMed ID: 23031625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs still influence health costs, but trend abating.
    Capitation Rates Data; 2003 Oct; 8(10):114-20. PubMed ID: 14621548
    [No Abstract]   [Full Text] [Related]  

  • 12. Changes in Medicaid prescription volume and use in the wake of Medicare Part D implementation.
    Bruen BK; Miller LM
    Health Aff (Millwood); 2008; 27(1):196-202. PubMed ID: 18180495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing the medical homes model for children with asthma.
    Domino ME; Humble C; Lawrence WW; Wegner S
    Med Care; 2009 Nov; 47(11):1113-20. PubMed ID: 19786921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Explaining drug spending trends: does perception match reality?
    Dubois RW; Chawla AJ; Neslusan CA; Smith MW; Wade S
    Health Aff (Millwood); 2000; 19(2):231-9. PubMed ID: 10718037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cluster analysis of state Medicaid prescription drug benefit programs based on potential determinants of per capita drug expenditure.
    Roy S; Madhavan SS
    Res Social Adm Pharm; 2009 Mar; 5(1):51-62. PubMed ID: 19285289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How similar are states' Medicaid preferred drug lists?
    Ketcham JD; Ngai JK
    Am J Manag Care; 2008 Nov; 14(11 Suppl):SP46-52. PubMed ID: 18991481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability and growth in spending for outpatient specialty pharmaceuticals.
    Mullins CD; DeVries AR; Hsu VD; Meng F; Palumbo FB
    Health Aff (Millwood); 2005; 24(4):1117-27. PubMed ID: 16012152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-altered states. As pharmaceutical spending continues to soar, state legislatures are taking bold steps to rein in their costs.
    Tieman J
    Mod Healthc; 2002 Apr; 32(17):28-31. PubMed ID: 12024771
    [No Abstract]   [Full Text] [Related]  

  • 19. National health spending in 2007: slower drug spending contributes to lowest rate of overall growth since 1998.
    Hartman M; Martin A; McDonnell P; Catlin A;
    Health Aff (Millwood); 2009; 28(1):246-61. PubMed ID: 19124877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Indiana Chronic Disease Management Program's impact on medicaid claims: a longitudinal, statewide evaluation.
    Katz BP; Holmes AM; Stump TE; Downs SM; Zillich AJ; Ackermann RT; Inui TS
    Med Care; 2009 Feb; 47(2):154-60. PubMed ID: 19169115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.